Managing diabetes in 2026 is changing for thousands of people across the UK. Abbott has officially started discontinuing the FreeStyle Libre 3 sensor, replacing it with the newer FreeStyle Libre 3 Plus, a sensor designed to support modern diabetes management better.
For anyone currently using FreeStyle Libre 3 for continuous glucose monitoring, this transition affects future prescriptions, sensor availability, and daily routines. Understanding what’s changing — and acting early — will help you avoid interruptions and continue monitoring with confidence.
At Diabetes Pharmacy, we help UK users stay informed and prepared during important technology transitions like this.
Why the FreeStyle Libre 3 Is Being Discontinued
Abbott’s decision to phase out the FreeStyle Libre 3 is part of a wider move toward simplifying its product range. Rather than maintaining multiple similar sensors, Abbott is consolidating users onto a single, higher-performance CGM standard.
The FreeStyle Libre 3 Plus builds on existing technology while offering greater flexibility across age groups, treatment types, and future integrations. This approach helps Abbott maintain consistent manufacturing, stronger clinical performance, and better long-term compatibility with automated insulin delivery systems.
For UK users, this means fewer product variations — but a more future-ready CGM solution.
UK Timeline: When the Change Takes Effect
The transition has already begun, but March 2026 is the key deadline UK users need to remember. While some regions started receiving Libre 3 Plus sensors in late 2025, the standard Libre 3 will no longer be supplied in the UK after March 2026.
If your prescription still lists FreeStyle Libre 3, it must be updated before this cutoff. Leaving it unchanged could lead to delays or gaps in CGM supply once older stock runs out.
What’s New With the FreeStyle Libre 3 Plus
The FreeStyle Libre 3 Plus isn’t a completely new device. Instead, it’s a refined upgrade that keeps the same compact size while introducing practical improvements that matter in everyday use.
The most noticeable change is the extended wear time. The Libre 3 Plus lasts 15 days, compared to the previous 14-day sensor. Over the course of a year, this reduces the number of sensor changes, making CGM use more convenient and slightly more cost-efficient.
Another important improvement is the expanded age approval. The Libre 3 Plus can now be used by children as young as 2 years old, offering families managing Type 1 diabetes in young children a safer and more inclusive option.
The Plus model is also designed to work with automated insulin delivery (AID) systems, including mylife Loop. This allows glucose readings to feed directly into compatible insulin pumps, supporting automated dose adjustments — a major step toward closed-loop care.
Finally, Abbott reports improved accuracy, particularly during low-glucose events and rapid glucose changes, helping reduce false alerts and unnecessary corrections.
What UK Users Must Do to Transition Smoothly
This change does not happen automatically, and the most important step is updating your prescription.
Because the FreeStyle Libre 3 Plus is classified as a separate medical device, pharmacies cannot substitute it for a Libre 3 without explicit approval. You’ll need to speak with your GP or diabetes specialist and request a new prescription that clearly states “FreeStyle Libre 3 Plus.”
It’s best to do this well before your current sensors run out, especially if you rely on repeat prescriptions.
App and Reader Compatibility: What Stays the Same
One reassuring aspect of this transition is that your digital setup does not need to change. The existing FreeStyle Libre 3 app works seamlessly with the Plus sensor, and the Libre 3 reader remains compatible after a simple startup process.
This means no new downloads, no additional hardware costs, and no learning curve — just a new sensor with added benefits.
Important Safety Notice UK Users Should Not Ignore
Alongside the planned phase-out, Abbott issued an Urgent Field Safety Notice in late 2025 that remains relevant in 2026.
A manufacturing issue affected a limited number of FreeStyle Libre 3 and Libre 3 Plus sensors, causing them to display incorrectly low glucose readings. This is significant because false lows can lead to unnecessary carbohydrate intake or skipped insulin doses.
If you currently have Libre sensors at home, it’s essential to check whether they are affected.
You should:
- Locate the sensor serial number (in your app, reader, or packaging)
- Verify it using Abbott’s official online checker
- Discontinue and replace affected sensors immediately (Abbott provides replacements)
This step protects your safety and ensures accurate glucose management.
How to Manage Your Current Sensor Stock
If you still have unused 14-day Libre 3 sensors, NHS guidance suggests using them before switching to the new 15-day Libre 3 Plus, provided they are not part of the safety recall. This avoids unnecessary waste and allows for a smoother transition.
Once your prescription is updated, future supplies should be ordered as FreeStyle Libre 3 Plus only.
You can explore CGM sensors and diabetes supplies through the Diabetes Pharmacy online shop, which supports UK users with trusted products and reliable delivery.
Why the Libre 3 Plus Transition Is a Positive Step
While any change in medical technology can feel disruptive, this transition brings meaningful benefits. Longer wear time reduces daily hassle, improved accuracy increases confidence, and pump compatibility supports smarter insulin management.
Most importantly, the Libre 3 Plus aligns with the future of personalised, automated diabetes care, helping users spend less time worrying about numbers and more time living their lives.
Get Help During the Transition
If you’re unsure how to discuss this change with your healthcare provider, our guide on how to work with your doctor and pharmacist explains how to ask the right questions and update prescriptions smoothly.
To learn more about our role in UK diabetes care, visit our About Us page. For personalised assistance, reach out through Contact Us. You can also explore more practical guides in our diabetes blog section.
Final Thoughts for UK Libre Users
The transition to FreeStyle Libre 3 Plus represents more than a routine product update — it reflects the wider direction of diabetes care in the UK. With longer wear time, improved accuracy, and better integration with automated insulin delivery systems, the Libre 3 Plus is designed to reduce daily effort while supporting safer, more responsive glucose management. For most users, this change will feel familiar but noticeably smoother over time.
To ensure a stress-free transition, it’s important to take action early. Updating your prescription before the March 2026 deadline, checking your existing sensors against the recent safety notice, and understanding how the Plus model fits into your current routine will help avoid gaps in monitoring. Small steps taken now can prevent last-minute disruptions later.
With trusted access to sensors, clear guidance, and ongoing support from Diabetes Pharmacy, UK users can move into this next phase of diabetes management with confidence. By staying informed and prepared, the shift to FreeStyle Libre 3 Plus becomes a positive step toward more reliable, personalised, and future-ready diabetes care.
